Hormone & Metabolic Testing

Anatara Medicine evaluates comprehensive hormone, cardiac, and metabolic status as part of its personalised diagnostic approach. Panels include sexual wellness hormone assessment for men (testosterone, LH, FSH, estradiol, SHBG, erectile dysfunction workup) and women (oestrogen, progesterone, FSH, LH for menopause and perimenopause). Hormones are also assessed within longevity and HealthMap panels. Findings inform personalised therapeutic protocols.

Anatara Medicine's hormone and metabolic testing integrates hormonal assessment as an essential layer of its Convergence Medicine diagnostic framework rather than treating it as a standalone panel service. Hormonal status intersects with virtually every system the clinic addresses — cardiovascular, neurological, immune, metabolic, and psychological wellbeing — making comprehensive hormone evaluation a baseline requirement for accurate clinical picture-building. For men, the sexual wellness and longevity assessment includes evaluation of total and free testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), estradiol, sex hormone binding globulin (SHBG), dihydrotestosterone (DHT), and prolactin. This panel characterises both primary (testicular) and secondary (hypothalamic-pituitary) hypogonadism, informs erectile dysfunction workup, and provides the baseline for any hormone optimisation discussions. Thyroid function (TSH, free T3, free T4, reverse T3, thyroid antibodies) and adrenal markers (cortisol curve, DHEA-S) are assessed in the context of fatigue, cognitive decline, and immune dysregulation. For women, the clinic assesses oestrogen (E1, E2, E3), progesterone, FSH, LH, SHBG, testosterone, and DHEA-S to characterise perimenopause and menopause transition, cycle-related dysfunction, and androgen excess. The assessment also includes markers relevant to bone health and cardiovascular risk in the peri- and postmenopausal context. All hormone panels are interpreted within the full diagnostic context — including nutrient status, microbiome results, and genomic variants that affect hormone metabolism (e.g. COMT, CYP1B1 for oestrogen detoxification) — enabling the clinical team to develop targeted, evidence-informed hormone support strategies. Findings are presented during follow-up consultation with a physician. Testing is typically bundled into the initial diagnostic package or the HealthMap programme.